Superiority of <scp>Low‐Dose</scp> Benzbromarone to <scp>Low‐Dose</scp> Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid UnderexcretionFei Yan, Changgui Li, Zijing Ran et al.|Arthritis & Rheumatology|2022Cited by 60
Metabolomics and Machine Learning Identify Metabolic Differences and Potential Biomarkers for Frequent Versus Infrequent Gout FlaresMing Wang, Changgui Li, Rui Li et al.|Arthritis & Rheumatology|2023Cited by 32
Hyperuricemia Subtypes Classified According to Renal Uric Acid Handling Manifesting Distinct Phenotypic and Genetic Profiles in People With GoutHan Qi, Changgui Li, Mingshu Sun et al.|Arthritis & Rheumatology|2024Cited by 13
Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary goutHan Qi, Changgui Li, Mingshu Sun et al.|Arthritis Research & Therapy|2023Cited by 10
Superiority of <scp>Low‐Dose</scp> Benzbromarone <scp>Add‐On</scp> to <scp>Low‐Dose</scp> Febuxostat Compared With Febuxostat Monotherapy in Gout With <scp>Combined‐Type</scp> HyperuricemiaXiaomei Xue, Changgui Li, Mingshu Sun et al.|Arthritis Care & Research|2023Cited by 10